Antiviral Drug Discovery and Development Center (AD3C)
抗病毒药物发现与开发中心(AD3C)
基本信息
- 批准号:10380660
- 负责人:
- 金额:$ 750万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-07 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvisory CommitteesAlphavirusAnimal ModelAnimal TestingAntiviral AgentsBackBiodistributionBiological AssayBiological AvailabilityBiologyChemicalsCollaborationsCoronavirusCountryDataDengueDevelopmentDrug KineticsDrug ScreeningEmerging Communicable DiseasesEvaluationEvolutionFlavivirusFormulationFosteringGoalsGrantHumanImmunityImmunologyIn VitroInfectionInfluenzaInfluenza A virusInstitutesLaboratoriesLeadLegal patentLettersMiddle East Respiratory SyndromeModelingMonitorNational Institute of Allergy and Infectious DiseaseNucleosidesNucleotidesOutcomePathogenesisPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePharmacologyPreparationProcessPropertyRNA VirusesRecordsResearch PersonnelResistanceResistance developmentRiskScienceScientistSevere Acute Respiratory SyndromeStructureTestingTherapeuticTherapeutic IndexToxicologyTranslational ResearchTravelVariantVenezuelan Equine Encephalitis VirusViralViral PathogenesisVirusVirus DiseasesVirus ReplicationWest Nile virusWorkZIKAantiviral drug developmentchikungunyadrug developmentdrug discoverydrug modificationexperiencegene functionhuman diseasein vivomembernovelnovel therapeuticsphase 1 studypre-clinicalprogramsresponsesmall molecule therapeuticssuccesssymposiumsynergismtherapy developmenttranslation to humansvirology
项目摘要
OVERALL SUMMARY
In response to RFA-AI-17-042, Centers of Excellence in Translational Research, we propose to develop small
molecule therapeutics for the treatment of emerging viral infections under the umbrella of the Antiviral Drug
Discovery and Development Center. We are a team of scientists experienced in virology, viral immunology,
pathogenesis, medicinal chemistry, and translation to human disease. We have established four Projects – each
of which addresses infections identified as high priority by the National Institute of Allergy and Infectious
Diseases (NIAID). Members of several genera of RNA viruses will be studied as they are major causes of human
disease, bioterrorist threats, or emerging infectious diseases. Pharmacological control of these viruses remains
limited. Our Projects will focus on (1) coronaviruses that cause SARS and MERS, (2) alphaviruses including
Venezuelan equine encephalitis virus and chikungunya, 3) flaviviruses including dengue, West Nile virus, and
Zika and 4) influenza A virus. We will utilize lead molecules identified in recent years by AD3C to perform
therapeutic proof of principle studies in animal models within the first two years of the grant. Importantly, we will
additionally evaluate a limited number of novel compounds provided by our collaborators, the Emory Institute for
Drug Discovery (EIDD) and Gilead Sciences in order to have back-up platforms to address the potential
development of resistance. Expertise exists in the AD3C for IND enabling studies, IND preparation and filing as
well as Phase I studies, should suitable candidates be identified. The projects are supported by three Cores: the
Administrative Core (Core A), the Assay Core (Core B), and the Medicinal Chemistry and Lead Development
Core (Core C). The organization and interaction between all Projects and Cores will be monitored by the
Administrative Core. An Executive Committee (EC) will consist of all Project and Core Leads to review data on
monthly conference calls, in order to provide further direction and foster project interactions. An external
Scientific Advisory Committee (SAC) will be established to provide evaluation of the project progress and
facilitate “Go/No-Go” decisions on a regular basis. Since its inception, AD3C has already contributed significant
data to an IND filed for MERS and two patent applications for compounds with activity against chikungunya,
illustrating the success of our collaborative model.
整体总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD J. WHITLEY其他文献
RICHARD J. WHITLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD J. WHITLEY', 18)}}的其他基金
Antiviral Drug Discovery and Development Center (AD3C)
抗病毒药物发现与开发中心(AD3C)
- 批准号:
9888306 - 财政年份:2019
- 资助金额:
$ 750万 - 项目类别:
Antiviral Drug Discovery and Development Center (AD3C)
抗病毒药物发现与开发中心(AD3C)
- 批准号:
10115578 - 财政年份:2019
- 资助金额:
$ 750万 - 项目类别:
Antiviral Drug Discovery and Development Center (AD3C)
抗病毒药物发现与开发中心(AD3C)
- 批准号:
10580015 - 财政年份:2019
- 资助金额:
$ 750万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 750万 - 项目类别:
Standard Grant